The highest price of Moderna stock till date occurred on December 18, 2020, when it peaked at $178.50 per share. This was largely attributed to the announcement of Moderna’s COVID-19 vaccine receiving emergency use authorization (EUA) from the United States Food and Drug Administration (FDA).
Moderna’s COVID-19 vaccine was developed using mRNA technology, and it demonstrated an efficacy rate of 94.5% in clinical trials. The announcement of the vaccine’s approval sent shockwaves across the biotech industry, and Moderna’s shares skyrocketed, propelling the company’s market value to nearly $65 billion.
Investors were excited about the prospect of Moderna’s COVID-19 vaccine being a game-changer in the battle against the pandemic, which led to a frenzy of buying activity, driving up the price of the stock.
The surge in Moderna’s stock price was also fueled by positive news from rival vaccine manufacturers, such as Pfizer/BioNTech and Johnson & Johnson, which also received EUAs for their respective COVID-19 vaccines. The collective optimism surrounding the vaccines sparked a rally in the stock market, with investors looking to capitalize on the strong growth prospects of the biotech sector.
However, it is important to note that stock prices are inherently volatile, and they can fluctuate in response to a variety of factors, including news events, market sentiment, and economic conditions. In fact, Moderna’s stock price has witnessed sharp swings in both directions since its initial public offering (IPO) in 2018, and it is likely to continue to experience fluctuations in the future.
As with any investment, it is important to conduct proper research and exercise caution when investing in Moderna or any other stocks.
Table of Contents
What is Moderna projected stock price?
Moderna is a biotechnology company that develops pharmaceuticals and vaccines. The stock price of the company is influenced by a variety of factors, including clinical trial results, regulatory approvals, competition, political trends, and global economic conditions.
One of the primary drivers of Moderna’s stock price is the success of its COVID-19 vaccine, mRNA-1273, that it developed in collaboration with the National Institutes of Health (NIH). Moderna’s COVID-19 vaccine has shown high efficacy rates in clinical trials and received regulatory approvals from many countries.
The continued success of mRNA-1273 and the development of other vaccines by Moderna could potentially increase the demand for Moderna’s shares, resulting in a higher stock price.
Additionally, the intense competition in the pharmaceutical industry could also impact Moderna’s stock price. Many companies are also developing COVID-19 vaccines, including Pfizer and BioNTech. If Moderna’s vaccine market share decreases due to increased competition, investors may be less optimistic about the company’s financial growth potential, which could lead to a decrease in Moderna’s stock price.
The stock price for Moderna could also be impacted by global economic conditions. Economic instability or a slowdown in the economy could result in decreased demand for pharmaceuticals, as individuals may reduce their spending on non-essential drugs.
Many factors contribute to Moderna’s stock price, and it’s difficult to predict its future trend. It’s essential to evaluate various factors such as the market trends, the company’s financial performance, and its developmental pipeline before investing in Moderna or any other pharmaceutical company.
How many shares does Moderna have outstanding?
Outstanding shares refer to the total number of shares that a company has issued to investors or shareholders, including those owned by insiders and institutional investors. These outstanding shares represent the equity ownership of the company and determine the percentage of ownership for each shareholder.
To determine the number of outstanding shares of Moderna, we need to look at the company’s financial statements or other reliable sources of information such as financial news websites, regulatory filings, or investor relations websites.
As of September 30, 2021, Moderna reported having 388.4 million shares outstanding. This number may change over time as the company may issue additional shares through stock offerings or buybacks. It’s important to note that outstanding shares do not include shares that are held in treasury or reserved for employee stock options or other purposes.
As of September 30, 2021, Moderna has 388.4 million shares outstanding. This number may be subject to change based on company actions and market conditions. It’s always important for investors to research and verify the latest figures before making any investment decisions.
Who are the major stockholders in Moderna?
Moderna is a biotechnology company that specializes in messenger RNA technology to develop innovative medicines and vaccines. It was founded in 2010 by a group of scientists and entrepreneurs, including Noubar Afeyan, Robert Langer, Derrick Rossi, and Kenneth Chien, and has since grown into a publicly traded company with a market capitalization of over $150 billion.
As of June 30, 2021, the major stockholders in Moderna include institutional investors, mutual funds, and the company’s executives and directors.
One of the largest institutional investors in Moderna is the Vanguard Group, Inc., which holds over 32 million shares of the company as of its latest filing with the SEC. Other notable institutional investors in the company include BlackRock, Inc., Fidelity Management & Research Company, and Capital Research & Management Company.
These large asset management firms hold significant stakes in Moderna on behalf of their clients, such as pension funds, endowments, and high net worth individuals.
In addition to institutional investors, Moderna’s executives and directors also own a substantial amount of the company’s stock. For example, Noubar Afeyan, who co-founded Moderna and serves as its chairman, owns over 5 million shares, which are currently worth more than $1.6 billion. Stéphane Bancel, the company’s CEO, also holds a significant amount of Moderna stock, with over 2 million shares worth nearly $700 million.
Other executives and directors, such as Lori Henderson, Juan Andres, and Elizabeth Nabel, also own millions of dollars’ worth of Moderna shares.
While the majority of Moderna’s stock is owned by institutional investors and company insiders, there are also some individual investors who have purchased shares on the open market. These investors include day traders, retail investors, and small hedge funds, who may be attracted to Moderna’s potential for rapid growth and innovation in the biotech industry.
Moderna’S major stockholders are a diverse group of institutional investors, executives, and directors with a shared interest in the company’s long-term success. As Moderna continues to develop new therapeutics and vaccines using its groundbreaking messenger RNA technology, it is likely that the composition of its stockholders will continue to evolve, with new investors seeking to participate in the company’s growth and potential for future returns.
What mutual funds hold Moderna?
Moderna, Inc. is a biotechnology company that specializes in the development of transformative medicines based on messenger RNA (mRNA) technology. The company has gained significant attention in the past year for its efforts to develop a COVID-19 vaccine that has been authorized for emergency use by regulatory authorities in various countries worldwide.
Moderna has also developed other mRNA-based therapies and vaccines for various diseases.
Mutual funds provide diversified investment opportunities to investors, allowing them to invest in a pool of assets managed by professional portfolio managers. These funds typically hold various securities such as stocks, bonds, and other financial instruments, with the intention of achieving a specific investment objective.
Several mutual funds invest in Moderna, either directly or indirectly. Some mutual funds invest in Moderna as part of their portfolio of biotechnology companies, while others invest in funds that hold Moderna as one of their constituents. However, it is important to bear in mind that mutual fund holdings can change frequently depending on market conditions, fund manager decisions, and other factors.
One mutual fund that holds a significant stake in Moderna is the ARK Genomic Revolution ETF (ARKG). This fund is managed by ARK Investment Management, LLC, which specializes in investing in companies that are at the forefront of transformative technologies, including genomics, robotics, and artificial intelligence.
As of August 2021, the ARKG fund held approximately 6.7% of its portfolio in Moderna, making it one of the largest holdings for the fund.
Other mutual funds that invest in Moderna include the Invesco NASDAQ Biotechnology ETF (IBB), the Fidelity Select Biotechnology Portfolio (FBIOX), and the T. Rowe Price Health Sciences Fund (PRHSX). The IBB and FBIOX are specifically focused on biotechnology companies and hold shares of Moderna as part of their broader portfolios.
The PRHSX fund is focused on healthcare and life sciences companies, and Moderna is one of its top holdings.
Several mutual funds hold Moderna as part of their diversified portfolios. However, it is vital to research each individual fund’s investment strategy, fees, and past performance before making an investment decision. Moreover, it is essential to understand that mutual fund investments come with risk, and past performance is not a guarantee of future results.
Who owns the most shares of Moderna?
Moderna, Inc. was founded in 2010 and has since become a leading biotechnology company in the field of mRNA therapeutics and vaccines. With the successful development of its COVID-19 vaccine, Moderna has received unprecedented attention and investment in recent months, and this has led many to wonder who owns the most shares in the company.
As of the latest available data from June 30, 2021, the largest institutional shareholder of Moderna is a company called Vanguard Group, Inc., which owns 20,987,922 shares or 9.72% of the outstanding common stock. Vanguard is a leading investment management firm, and its fund managers invest on behalf of their clients, which can include individual investors, institutions, and retirement plans.
The second-largest institutional shareholder of Moderna is BlackRock, Inc., with 18,735,580 shares or 8.66% of the outstanding common stock. BlackRock is another well-known investment management firm that provides various investment services to clients around the world. Like Vanguard, BlackRock invests on behalf of its clients and can hold stocks in numerous companies.
Apart from these, there are many other large institutional investors that own significant stakes in Moderna, including Capital Research Global Investors, Geode Capital Management, and Fidelity Management & Research Company. Additionally, Moderna’s co-founder and Chairman Noubar Afeyan is reported to hold over 100,000 shares in the company, as of June 2021.
While several large institutional shareholders own significant stakes in Moderna, the company remains majority-owned by its founders, executives, and employees, who together hold over 56% of the outstanding common stock. This is typical of many biotech companies, where ownership is concentrated among a small group of investors who are closely involved with the company’s operations and growth.
Who owns most stock in Pfizer?
As of August 2021, the largest shareholder of Pfizer, Inc. is The Vanguard Group, Inc., which owns approximately 7.74% of the company’s outstanding shares. Other major institutional shareholders of Pfizer include BlackRock, Inc. with a 6.98% stake and State Street Corporation with a 4.22% stake. Private shareholders also hold a significant percentage of Pfizer’s stock, with CEO Albert Bourla owning nearly 0.09% of the company’s outstanding shares as of August 2021.
Pfizer has a diversified shareholder base that includes institutional investors, mutual funds, and individual shareholders. It is worth noting that ownership of Pfizer’s stock can change quickly due to stock trading, making it important to regularly monitor changes in ownership and potential impact on the company’s financial performance.
Who invested in Moderna vaccine?
The Moderna vaccine, widely known as the mRNA-1273 COVID-19 vaccine, has been one of the most widely-used vaccines in the world since its approval in December 2020. It is a messenger RNA-based vaccine that has been developed to help combat the spread of the COVID-19 virus worldwide. However, the development of the Moderna vaccine did not just happen overnight; it was the result of many years of research, development, and a lot of investment.
The Moderna vaccine was developed by the biotech company, Moderna Therapeutics, which is based in Cambridge, Massachusetts. Since its founding in 2010, Moderna Therapeutics has been focused on developing messenger RNA-based therapeutics and vaccines. The company has been led by a team of experienced scientists, investors, and execs who have helped to guide the company’s growth and success.
When it comes to investment in the Moderna vaccine, the funding for the research and development was initially provided by various venture capital firms, including Flagship Pioneering, based in Boston. Furthermore, in 2013, the company raised a whopping $500 million from various investors, such as AstraZeneca, Alexion Pharmaceuticals, and more.
In 2015, Moderna also entered into a strategic partnership with Merck, which involved Merck investing $100 million in the company. According to public records, Merck sold its stake in Moderna at some point in 2019.
Apart from these big investors, Moderna has also been backed by a number of government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH), which have provided significant funding for the development of the Moderna vaccine.
It is clear that the development of the Moderna vaccine was supported by a range of investors, including venture capital firms, pharmaceutical companies, government agencies, and more. Without a doubt, the collective investment in Moderna Therapeutics and the vaccine has been incredibly significant, which has helped to fast-track the development and rollout of the mRNA-1273 COVID-19 vaccine.
Who is the owner of Moderna company?
Moderna is a publicly traded biotech company, which means that it is owned by many investors who have purchased shares of the company on the stock market. As of September 2021, the largest individual shareholder is Stéphane Bancel, who is also the current CEO of Moderna. He owns approximately 8.26% of the company’s shares.
The other major shareholders of Moderna include venture capital firms, mutual funds, and institutional investors.
Moderna was founded in 2010 by a team of leading scientists and entrepreneurs, with the goal of using messenger RNA (mRNA) technology to develop a new generation of medicines. The company went public in 2018 and has since become one of the most valuable biotech companies in the world, with a market capitalization of over $100 billion.
While Bancel is the largest individual shareholder of Moderna, he is not the majority owner, as the company is owned by a wide range of investors. As a publicly traded company, Moderna has a responsibility to its shareholders to operate in their best interests and maximize shareholder value. This means that decisions about the company’s direction and strategy are made by a board of directors who are elected by the shareholders, rather than by any single individual or group.
Who are the shareholders of BioNTech?
BioNTech SE is a German biotechnology company focused on developing personalized cancer treatments and vaccines for infectious diseases. The company was founded in 2008 by Dr. Ugur Sahin and Dr. Özlem Türeci and has since become a leader in the field of novel immunotherapies. As a publicly-traded company, BioNTech has a diverse group of shareholders, consisting of both institutional and individual investors.
The major shareholders of BioNTech are the company founders, Dr. Sahin and Dr. Türeci, who own a combined 17.8% of the company’s shares. The company’s largest institutional shareholders are the investment firms Fidelity and BlackRock, who own 6.14% and 4.99% of the shares, respectively. Other significant institutional shareholders include Vanguard Group, Morgan Stanley, and Capital Group Companies.
In addition to institutional investors, BioNTech also has a large number of individual investors who hold shares through various brokerage firms.
In January 2021, BioNTech became a household name after partnering with Pfizer to develop a highly effective COVID-19 vaccine. The success of the vaccine has led to an increase in investor interest and subsequent share price growth. As of May 2021, BioNTech’s market capitalization is approximately $97 billion, making it one of the most valuable biotech companies in the world.
Biontech’S shareholders represent a diverse group of investors from around the world who are attracted to the company’s groundbreaking research and potential for growth in the future. As the company continues to expand and develop new treatments, it is likely that its list of shareholders will continue to evolve and change over time.
Why is Moderna shares dropping?
There are various reasons that could be contributing to the drop in Moderna shares. One of the primary reasons is that the company’s COVID-19 vaccine has faced stiff competition from other vaccine makers, particularly Pfizer-BioNTech whose vaccine was the first to receive emergency use authorization in the United States.
Another reason behind Moderna’s declining stock price could be the concerns over the company’s valuation. The biotech sector has seen a significant surge in evaluation, and investors are becoming increasingly cautious about whether Moderna is overvalued or not.
Another potential factor is the recent news that the US government will not be purchasing additional doses of the Moderna vaccine, as they already have enough to vaccinate the population. This news could be interpreted as a blow to Moderna, as it will mean a significant reduction in revenue for the company.
Additionally, investors are closely monitoring the company’s pipeline of drugs to see if any of them will be successful. If there are any hitches or disappointments in the pipeline, it could result in investor caution and a pullback in the company’s shares.
Finally, the overall market sentiment or economic conditions could also be playing a role in the decline of Moderna shares. The company’s stock price could be influenced by broader economic factors, and if there are concerns about economic growth, that could negatively impact Moderna’s shares. In short, a combination of these factors could be contributing to the drop in Moderna shares.
Is Moderna debt free?
Moderna is not completely debt-free, but it does have a strong financial position. As of March 31, 2021, the company had a cash and investment balance of $8.2 billion and generated $1.9 billion in revenue in the first quarter of 2021 alone. The company’s current assets also exceed its current liabilities, indicating that it has sufficient liquidity to meet its short-term obligations.
However, Moderna does have long-term debt in the form of convertible notes that can be redeemed for cash, stock, or a combination of the two. As of March 31, 2021, the principal amount of these convertible notes was $1.3 billion, which would represent a significant liability for many companies. Nevertheless, Moderna’s financial position is such that it has the means to address this debt and has not struggled to meet interest or principal payments to date.
Moderna’S financial performance has been impressive in recent years, driven by the success of its COVID-19 vaccine development program. The company has leveraged this success to raise additional capital through stock offerings, reducing its dependence on debt for funding. In short, while Moderna is not entirely debt-free, its financial position remains robust, with strong cash reserves and a sustainable level of long-term debt.
What is the book value of mRNA stock?
The book value of a company’s stock refers to the value of its assets minus liabilities that are recorded on its balance sheet. This value is also sometimes referred to as net asset value or shareholder equity. To find out the book value of mRNA’s stock, we need to examine its balance sheet and analyze the company’s assets and liabilities.
mRNA (Moderna Inc.) is a biotechnology company that develops and manufactures mRNA-based therapeutics and vaccines. Let’s look at the company’s most recent balance sheet to determine its book value.
As of December 31, 2020, mRNA reported total assets of $12.45 billion and total liabilities of $2.23 billion. This results in a shareholders’ equity of $10.22 billion ($12.45 billion – $2.23 billion).
Now, we need to determine how many outstanding shares the company has in order to calculate the book value per share. According to Moderna’s most recent quarterly report, as of January 26, 2021, the company had 387.8 million shares outstanding.
To determine the book value per share, we divide the total shareholders’ equity ($10.22 billion) by the number of outstanding shares (387.8 million). This results in a book value of $26.35 per share as of January 26, 2021.
It’s important to note that the book value of a stock isn’t always an accurate indicator of its true value. A company’s book value is based on its balance sheet and doesn’t take into account factors such as market trends, investor sentiment, or future growth potential. In other words, the book value may not reflect the current market value of the stock.
Therefore, while the book value of mRNA’s stock is $26.35 per share as of January 26, 2021, it’s important to consider other factors such as earnings reports, market trends and company management behavior to determine whether mRNA stock is a good investment or not.
Is Moderna just as good as Pfizer?
The answer to whether Moderna is just as good as Pfizer is not a straightforward one. Both Moderna and Pfizer use mRNA technology in their COVID-19 vaccines, which have been shown to be highly effective at preventing severe illness and hospitalization caused by the virus. Clinical trials have shown that both vaccines are around 95% effective at preventing symptomatic COVID-19 infection.
While the vaccines have many similarities, there are some differences between them. For example, the vaccines’ dosages are different, as Moderna’s vaccine requires two doses, spaced four weeks apart, while Pfizer’s vaccine requires two doses, spaced three weeks apart. Additionally, the storage requirements of the two vaccines are different, as Moderna’s vaccine can be stored at regular freezer temperatures, while Pfizer’s vaccine needs to be stored at ultra-low temperatures.
Although the vaccines’ effectiveness rates are similar, there is some evidence to suggest that Moderna’s vaccine may offer slightly better protection against severe illness and hospitalization. One study showed that Moderna’s vaccine was over 95% effective at preventing hospitalization, compared to Pfizer’s vaccine, which was around 75% effective at preventing hospitalization.
It is also worth noting that both vaccines have undergone rigorous testing and have been approved by multiple health regulatory agencies worldwide. The safety profile of both vaccines is also excellent, with only minor side effects reported in most cases.
Both Moderna and Pfizer’s COVID-19 vaccines are highly effective at preventing severe illness and hospitalization caused by the virus. While there are some differences between the two vaccines, they are both safe and have undergone extensive testing. the choice between the two vaccines may come down to availability and personal preference.
What is Moderna’s cost of debt?
Moderna is a biotechnology company that has been at the forefront of developing innovative messenger RNA (mRNA) therapeutics and vaccines. The company has been successful in raising large amounts of capital to fund its research and development activities, which includes both equity and debt financing.
The cost of debt for Moderna is the interest rate that the company pays on its outstanding debt. This includes any interest payments on bonds, loans, and other debt instruments that Moderna has issued or borrowed from banks, financial institutions, or other sources.
To determine Moderna’s cost of debt, the company’s financial statements need to be analyzed to identify the total amount of debt that the company has outstanding, the interest rates on each of these debts, and any associated fees or other costs.
Moderna has issued several bonds in recent years to raise capital, including a $1.35 billion convertible bond offering in 2021 that carries an interest rate of 1.25%. The company has also entered into a loan agreement with the European Investment Bank for €400 million, which carries an interest rate of 0.5%.
However, it is important to note that Moderna’s cost of debt may change over time as interest rates fluctuate and the company’s creditworthiness is reassessed based on its financial performance and market conditions.
While the exact cost of debt for Moderna will depend on the specifics of its outstanding debt instruments, the interest rates, fees, and other associated costs, the company’s recent bond offerings and loan agreements suggest that it has been able to secure funding at relatively low interest rates, reflecting the market’s confidence in its business model and future prospects.
